OKYO Pharma's neuropathic corneal pain study gets FDA approval, with Phase 2b/3 trial to launch this year.

OKYO Pharma's neuropathic corneal pain study has been greenlit by the FDA, allowing the company to launch a Phase 2b/3 clinical trial. The study targets a severely debilitating and underserved condition. Following a productive Type C meeting with the FDA, the company now has a clear line of sight to activate the clinical study. The goal is to enroll 120 subjects and complete the study by year-end, with top-line results expected in Q1 2027.